BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol. 2000;95:3469-3477. [PMID: 11151879 DOI: 10.1111/j.1572-0241.2000.03363.x] [Cited by in Crossref: 161] [Cited by in F6Publishing: 154] [Article Influence: 7.7] [Reference Citation Analysis]
Number Citing Articles
1 Zoccali M, Fichera A. Minimally invasive approaches for the treatment of inflammatory bowel disease. World J Gastroenterol 2012; 18(46): 6756-6763 [PMID: 23239913 DOI: 10.3748/wjg.v18.i46.6756] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
2 Cohen RD. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience. Inflamm Bowel Dis 2001;7:S17-22. [DOI: 10.1002/ibd.3780070505] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 1.9] [Reference Citation Analysis]
3 Bank S, Andersen PS, Burisch J, Pedersen N, Roug S, Galsgaard J, Turino SY, Brodersen JB, Rashid S, Rasmussen BK, Avlund S, Olesen TB, Hoffmann HJ, Nexø BA, Sode J, Vogel U, Andersen V. Genetically determined high activity of IL-12 and IL-18 in ulcerative colitis and TLR5 in Crohns disease were associated with non-response to anti-TNF therapy. Pharmacogenomics J 2018;18:87-97. [PMID: 28139755 DOI: 10.1038/tpj.2016.84] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
4 Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19-31. [PMID: 14699483 DOI: 10.1053/j.gastro.2003.10.047] [Cited by in Crossref: 638] [Cited by in F6Publishing: 556] [Article Influence: 35.4] [Reference Citation Analysis]
5 Franchimont N, Putzeys V, Collette J, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Franchimont D, Fiasse R, Pelckmans P, Malaise M, Belaiche J, Louis E. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Aliment Pharmacol Ther. 2004;20:607-614. [PMID: 15352908 DOI: 10.1111/j.1365-2036.2004.02152.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 46] [Article Influence: 3.2] [Reference Citation Analysis]
6 Teshima CW, Thompson A, Dhanoa L, Dieleman LA, Fedorak RN. Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort. Can J Gastroenterol 2009;23:348-52. [PMID: 19440565 DOI: 10.1155/2009/180840] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
7 Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol. 2002;97:2962-2972. [PMID: 12492177 DOI: 10.1111/j.1572-0241.2002.07093.x] [Cited by in Crossref: 138] [Cited by in F6Publishing: 130] [Article Influence: 7.3] [Reference Citation Analysis]
8 Ljung T, Axelsson L, Herulf M, Lundberg JO, Hellström PM. Early changes in rectal nitric oxide and mucosal inflammatory mediators in Crohn’s colitis in response to infliximab treatment: INFLIXIMAB TREATMENT AND RECTAL NITRIC OXIDE. Alimentary Pharmacology & Therapeutics 2007;25:925-32. [DOI: 10.1111/j.1365-2036.2007.03284.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
9 Rutgeerts PJ. Review article: the limitations of corticosteroid therapy in Crohn’s disease. Aliment Pharmacol Ther. 2001;15:1515-1525. [PMID: 11563990 DOI: 10.1046/j.1365-2036.2001.01060.x] [Cited by in Crossref: 97] [Cited by in F6Publishing: 84] [Article Influence: 4.9] [Reference Citation Analysis]
10 Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology. 2002;122:1592-1608. [PMID: 12016425 DOI: 10.1053/gast.2002.33426] [Cited by in Crossref: 226] [Cited by in F6Publishing: 198] [Article Influence: 11.3] [Reference Citation Analysis]
11 Rudolph SJ, Weinberg DI, Mccabe RP. Long-Term Durability of Crohn’s Disease Treatment with Infliximab. Dig Dis Sci 2008;53:1033-41. [DOI: 10.1007/s10620-007-9969-z] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.3] [Reference Citation Analysis]
12 Ryu K, Kim T. Therapeutic gene delivery using bioreducible polymers. Arch Pharm Res 2014;37:31-42. [DOI: 10.1007/s12272-013-0275-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
13 Bhatia JK, Korelitz BI, Panagopoulos G, Lobel E, Mirsky F, Sultan K, DiSanti W, Chun A, Keenan G, Mamun K. A prospective open-label trial of Remicade in patients with severe exacerbation of Crohn's disease requiring hospitalization: a comparison with outcomes previously observed in patients receiving intravenous hydrocortisone. J Clin Gastroenterol 2007;41:677-81. [PMID: 17667052 DOI: 10.1097/MCG.0b013e31802c2a23] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
14 Arnott ID, Watts D, Satsangi J. Azathioprine and anti-TNF alpha therapies in Crohn’s disease: a review of pharmacology, clinical efficacy and safety. Pharmacol Res. 2003;47:1-10. [PMID: 12526855 DOI: 10.1016/s1043-6618(02)00264-5] [Cited by in Crossref: 32] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
15 Ljung T, Karlén P, Schmidt D, Hellström PM, Lapidus A, Janczewska I, Sjöqvist U, Löfberg R. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut. 2004;53:849-853. [PMID: 15138212 DOI: 10.1136/gut.2003.018515] [Cited by in Crossref: 206] [Cited by in F6Publishing: 190] [Article Influence: 11.4] [Reference Citation Analysis]
16 Cuzzocrea S. Emerging biotherapies for inflammatory bowel disease. Expert Opinion on Emerging Drugs 2005;8:339-47. [DOI: 10.1517/14728214.8.2.339] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
17 Cottone M, Criscuoli V. Infliximab to treat Crohn's disease: an update. Clin Exp Gastroenterol 2011;4:227-38. [PMID: 22016584 DOI: 10.2147/CEG.S6440] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
18 Ardizzone S, Bianchi Porro G. Inflammatory bowel disease: new insights into pathogenesis and treatment. J Intern Med. 2002;252:475-496. [PMID: 12472908 DOI: 10.1046/j.1365-2796.2002.01067.x] [Cited by in Crossref: 114] [Cited by in F6Publishing: 103] [Article Influence: 6.0] [Reference Citation Analysis]
19 Orlando A, Colombo E, Kohn A, Biancone L, Rizzello F, Viscido A, Sostegni R, Benazzato L, Castiglione F, Papi C, Meucci G, Riegler G, Mocciaro F, Cassinotti A, Cosintino R, Geremia A, Morselli C, Angelucci E, Lavagna A, Rispo A, Bossa F, Scimeca D, Cottone M; Italian Multicentric Study Group on Infliximab. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study. Dig Liver Dis 2005;37:577-83. [PMID: 15886081 DOI: 10.1016/j.dld.2005.01.019] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 3.7] [Reference Citation Analysis]
20 Hamzaoglu H, Cooper J, Alsahli M, Falchuk KR, Peppercorn MA, Farrell RJ. Safety of infliximab in Crohn's disease: a large single-center experience. Inflamm Bowel Dis. 2010;16:2109-2116. [PMID: 20848473 DOI: 10.1002/ibd.21290] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
21 Atzeni F, Ardizzone S, Sarzi-Puttini P, Colombo E, Maconi G, De Portu S, Carrabba M, Bianchi Porro G. Autoantibody profile during short-term infliximab treatment for Crohn’s disease: a prospective cohort study. Aliment Pharmacol Ther. 2005;22:453-461. [PMID: 16128684 DOI: 10.1111/j.1365-2036.2005.02576.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
22 Sagiv Y, Kaminitz A, Lorberboum-galski H, Askenasy N, Yarkoni S. A Fusion Protein Composed of IL-2 and Caspase-3 Ameliorates the Outcome of Experimental Inflammatory Colitis. Annals of the New York Academy of Sciences 2009;1173:791-7. [DOI: 10.1111/j.1749-6632.2009.04877.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
23 Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P; ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549. [PMID: 12047962 DOI: 10.1016/s0140-6736(02)08512-4] [Cited by in Crossref: 2805] [Cited by in F6Publishing: 777] [Article Influence: 140.3] [Reference Citation Analysis]
24 Gupta AK, Skinner AR. A Review of the Use of Infliximab to Manage Cutaneous Dermatoses. J Cutan Med Surg 2004;8:77-89. [DOI: 10.1177/120347540400800202] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
25 Rundquist S, Sachs MC, Eriksson C, Olén O, Montgomery S, Halfvarson J; SWIBREG Study Group. Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers.Aliment Pharmacol Ther. 2021;53:471-483. [PMID: 33340426 DOI: 10.1111/apt.16193] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
26 Keshavarzian A, Farhadi A, Mutlu EA. New developments in the treatment of inflammatory bowel disease. Expert Opinion on Investigational Drugs 2005;11:365-85. [DOI: 10.1517/13543784.11.3.365] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
27 Plevy SE. Corticosteroid-sparing treatments in patients with Crohn's disease. Am J Gastroenterol 2002;97:1607-17. [PMID: 12135008 DOI: 10.1111/j.1572-0241.2002.05818.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
28 Itaba S, Iwasa T, Sadamoto Y, Nasu T, Misawa T, Inoue K, Shimokawa H, Nakamura K, Takayanagi R. Pneumocystis Pneumonia During Combined Therapy of Infliximab, Corticosteroid, and Azathioprine in a Patient with Crohn’s Disease. Dig Dis Sci 2007;52:1438-41. [DOI: 10.1007/s10620-006-9575-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
29 Lichtenstein GR. PRO: Maintenance Therapy Is Superior to Episodic Therapy. Am J Gastroenterology 2005;100:1433-5. [DOI: 10.1111/j.1572-0241.2005.50622_1.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
30 Caviglia R, Ribolsi M, Rizzi M, Emerenziani S, Annunziata ML, Cicala M. Maintenance of remission with infliximab in inflammatory bowel disease: Efficacy and safety long-term follow-up. World J Gastroenterol 2007; 13(39): 5238-5244 [PMID: 17876895 DOI: 10.3748/wjg.v13.i39.5238] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
31 Ljung T, Thomsen OØ, Vatn M, Karlén P, Karlsen LN, Tysk C, Nilsson SU, Kilander A, Gillberg R, Grip O, Lindgren S, Befrits R, Löfberg R. Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia. Scand J Gastroenterol 2007;42:221-7. [PMID: 17327942 DOI: 10.1080/00365520600979369] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
32 Bagul A. Ischaemic/reperfusion injury: Role of infliximab. World J Transplant 2012; 2(3): 35-40 [PMID: 24175194 DOI: 10.5500/wjt.v2.i3.35] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
33 Chang JC, Cohen RD. Medical management of severe ulcerative colitis. Gastroenterology Clinics of North America 2004;33:235-50. [DOI: 10.1016/j.gtc.2004.02.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
34 Smith SL, Singh P, Harding D, Lun D, Chambers JP. Thalidomide pharmacokinetics in sheep. N Z Vet J 2016;64:238-42. [PMID: 26727254 DOI: 10.1080/00480169.2015.1130663] [Reference Citation Analysis]
35 Domènech E, Esteve M, Gomollón F, Hinojosa J, Panés J, Obrador A, Gassull M. Recomendaciones GETECCU-2005 para el uso de infliximab (Remicade®) en la enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 2005;28:126-34. [DOI: 10.1157/13072012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
36 Miehsler W, Novacek G, Wenzl H, Vogelsang H, Knoflach P, Kaser A, Dejaco C, Petritsch W, Kapitan M, Maier H. A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis. 2010;4:221-256. [PMID: 21122513 DOI: 10.1016/j.crohns.2009.12.001] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 5.0] [Reference Citation Analysis]
37 Osterman MT, Lichtenstein GR. Infliximab in fistulizing Crohn's disease. Gastroenterol Clin North Am. 2006;35:795-820. [PMID: 17129814 DOI: 10.1016/j.gtc.2006.09.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
38 Meyer MM, Levine EJ. Acute hemorrhagic Crohn's disease controlled with infliximab. Inflamm Bowel Dis. 2009;15:1456-1457. [PMID: 19107774 DOI: 10.1002/ibd.20840] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
39 Sou S, Matsui T, Yao T, Yorioka M, Tsuda S, Kikuchi Y, Wada Y, Nagahama T, Yao K. CLINICAL AND ENDOSCOPIC HEALING AFTER INFLIXIMAB TREATMENT IN PATIENTS WITH CROHN's DISEASE. Dig Endosc 2006;18:29-33. [DOI: 10.1111/j.1443-1661.2006.00566.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
40 Rizzello F, Gionchetti P, Venturi A, Morselli C, Campieri M. The management of refractory Crohn's disease: REVIEW: MANAGEMENT OF REFRACTORY CROHN'S DISEASE. Alimentary Pharmacology & Therapeutics 2002;16:40-7. [DOI: 10.1046/j.1365-2036.16.s4.6.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
41 González-Lama Y, Vera MI, Calvo M, Abreu L. [Markers of the course of inflammatory bowel disease treated with immunomodulators or biological agents]. Gastroenterol Hepatol 2010;33:449-60. [PMID: 20122758 DOI: 10.1016/j.gastrohep.2009.11.005] [Reference Citation Analysis]
42 Vasudevan A, Gibson PR, Langenberg DRV. Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told? World J Gastroenterol 2017; 23(35): 6385-6402 [PMID: 29085188 DOI: 10.3748/wjg.v23.i35.6385] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
43 Su C, Lichtenstein GR. Are there predictors of Remicade treatment success or failure? Adv Drug Deliv Rev. 2005;57:237-245. [PMID: 15555740 DOI: 10.1016/j.addr.2004.08.006] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
44 Sun XL, Chen SY, Tao SS, Qiao LC, Chen HJ, Yang BL. Optimized timing of using infliximab in perianal fistulizing Crohn's disease. World J Gastroenterol 2020; 26(14): 1554-1563 [PMID: 32327905 DOI: 10.3748/wjg.v26.i14.1554] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
45 Ancowitz B, Shah SA. Infusion services in the gastroenterology practice. Gastrointest Endosc Clin N Am 2006;16:727-42. [PMID: 17098619 DOI: 10.1016/j.giec.2006.08.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
46 Rutgeerts P. A critical assessment of new therapies in inflammatory bowel disease. J Gastroenterol Hepatol. 2002;17 Suppl:S176-S185. [PMID: 12000604 DOI: 10.1046/j.1440-1746.17.s1.1.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 2.0] [Reference Citation Analysis]
47 Shah A, Alhusayen R, Amini-Nik S. The critical role of macrophages in the pathogenesis of hidradenitis suppurativa. Inflamm Res 2017;66:931-45. [PMID: 28656364 DOI: 10.1007/s00011-017-1074-y] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
48 Veres G, Baldassano RN, Mamula P. Infliximab therapy for pediatric Crohn's disease. Expert Opinion on Biological Therapy 2007;7:1869-80. [DOI: 10.1517/14712598.7.12.1869] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
49 Campi P, Benucci M, Manfredi M, Demoly P. Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-alpha antagonists. Curr Opin Allergy Clin Immunol 2007;7:393-403. [PMID: 17873578 DOI: 10.1097/ACI.0b013e3282ef96df] [Cited by in Crossref: 34] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
50 Klapman JB, Ene-stroescu D, Becker MA, Hanauer SB. A Lupus-like Syndrome Associated With Infliximab Therapy: . Inflammatory Bowel Diseases 2003;9:176-8. [DOI: 10.1097/00054725-200305000-00005] [Cited by in Crossref: 61] [Cited by in F6Publishing: 43] [Article Influence: 3.2] [Reference Citation Analysis]
51 Mamula P, Cohen SA, Ferry GD, Kirschner BS, Winter HS, Innes A, Patel J, Baldassano RN. CDP571, a Humanized Anti-Tumor Necrosis Factor-α Monoclonal Antibody in Pediatric Crohn’s Disease: . Inflammatory Bowel Diseases 2004;10:723-30. [DOI: 10.1097/00054725-200411000-00005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
52 Hagen JW, Magro CM, Crowson AN. Emerging Adverse Cutaneous Drug Reactions. Dermatologic Clinics 2012;30:695-730. [DOI: 10.1016/j.det.2012.06.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
53 Fichera A, Peng SL, Elisseou NM, Rubin MA, Hurst RD. Laparoscopy or conventional open surgery for patients with ileocolonic Crohn's disease? Surgery. 2007;142:566-571. [PMID: 17950349 DOI: 10.1016/j.surg.2007.08.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
54 van der Heide F, Dijkstra A, Weersma RK, Albersnagel FA, van der Logt EM, Faber KN, Sluiter WJ, Kleibeuker JH, Dijkstra G. Effects of active and passive smoking on disease course of Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2009;15:1199-207. [PMID: 19170191 DOI: 10.1002/ibd.20884] [Cited by in Crossref: 107] [Cited by in F6Publishing: 102] [Article Influence: 8.2] [Reference Citation Analysis]
55 Mamula P, Markowitz JE, Brown KA, Hurd LB, Piccoli DA, Baldassano RN. Infliximab as a Novel Therapy for Pediatric Ulcerative Colitis: . Journal of Pediatric Gastroenterology and Nutrition 2002;34:307-11. [DOI: 10.1097/00005176-200203000-00017] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 2.8] [Reference Citation Analysis]
56 Gisbert JP, Panés J. Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review. Am J Gastroenterol 2009;104:760-7. [DOI: 10.1038/ajg.2008.88] [Cited by in Crossref: 344] [Cited by in F6Publishing: 350] [Article Influence: 26.5] [Reference Citation Analysis]
57 Lichtenstein GR, Olson A, Travers S, Diamond RH, Chen DM, Pritchard ML, Feagan BG, Cohen RD, Salzberg BA, Hanauer SB. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn’s disease. Am J Gastroenterol. 2006;101:1030-1038. [PMID: 16606351 DOI: 10.1111/j.1572-0241.2006.00463.x] [Cited by in Crossref: 139] [Cited by in F6Publishing: 124] [Article Influence: 8.7] [Reference Citation Analysis]
58 Domènech E, Esteve-comas M, Gomollón F, Hinojosa J, Obrador A, Panés J, Gassull M. Recomendaciones para el uso de infliximab (Remicade®) en la enfermedad de Crohn.GETECCU 2001. Gastroenterología y Hepatología 2002;25:162-9. [DOI: 10.1016/s0210-5705(02)79012-2] [Cited by in Crossref: 11] [Article Influence: 0.6] [Reference Citation Analysis]
59 Kim YJ, Kim JW, Lee CK, Park HJ, Shim JJ, Jang JY, Dong SH, Kim HJ, Kim BH, Chang YW. [Clinical outcome of treatment with infliximab in Crohn's disease: a single-center experience]. Korean J Gastroenterol 2013;61:270-8. [PMID: 23756669 DOI: 10.4166/kjg.2013.61.5.270] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
60 Tadbiri S, Peyrin-Biroulet L, Serrero M, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Gilletta C, Gagniere C, Vuitton L, Viennot S, Aubourg A, Pelletier AL, Bouguen G, Abitbol V, Fumery M, Claudepierre P, Bouhnik Y, Amiot A; GETAID OBSERV-IBD study group. Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. Aliment Pharmacol Ther. 2018;47:485-493. [PMID: 29250803 DOI: 10.1111/apt.14419] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 11.6] [Reference Citation Analysis]
61 Gül Ü, Gönül M, Kiliç A, Erdem R, Çakmak SK, Gündüz H. Treatment of psoriatic arthritis with etanercept, methotrexate, and cyclosporin A. Clinical Therapeutics 2006;28:251-4. [DOI: 10.1016/j.clinthera.2006.02.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
62 Staros EB. Molecular Discoveries Alter Our View of Inflammatory Bowel Disease: A Review From Scientific, Clinical, and Laboratory Perspectives. Am J Clin Pathol 2003;119:524-39. [DOI: 10.1309/7w3etl9nq9rhhx61] [Cited by in Crossref: 7] [Article Influence: 0.4] [Reference Citation Analysis]
63 Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R;  REACH Study Group. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007;132:863-73; quiz 1165. [PMID: 17324398 DOI: 10.1053/j.gastro.2006.12.003] [Cited by in Crossref: 545] [Cited by in F6Publishing: 473] [Article Influence: 34.1] [Reference Citation Analysis]
64 Cohen RD. Infliximab as First-Line Therapy for Severe Crohn's Disease?: . Inflammatory Bowel Diseases 2002;8:58-9. [DOI: 10.1097/00054725-200201000-00010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
65 Riegert-Johnson DL, Godfrey JA, Myers JL, Hubmayr RD, Sandborn WJ, Loftus EV. Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion. Inflamm Bowel Dis. 2002;8:186-191. [PMID: 11979139 DOI: 10.1097/00054725-200205000-00005] [Cited by in Crossref: 66] [Cited by in F6Publishing: 45] [Article Influence: 3.3] [Reference Citation Analysis]
66 Hanauer SB. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Gut 2007;56:1181-3. [PMID: 17698862 DOI: 10.1136/gut.2006.115980] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
67 Comerford LW, Bickston SJ. Treatment of luminal and fistulizing Crohn's disease with infliximab. Gastroenterol Clin North Am. 2004;33:387-406, xi. [PMID: 15177545 DOI: 10.1016/j.gtc.2004.02.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
68 D’Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm M. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011;106:199-212; quiz 213. [PMID: 21045814 DOI: 10.1038/ajg.2010.392] [Cited by in Crossref: 263] [Cited by in F6Publishing: 256] [Article Influence: 21.9] [Reference Citation Analysis]
69 Poupardin C, Lémann M, Gendre J, Sabaté J, Marteau P, Chaussade S, Delchier J, Bouhnik Y, Chaput J, Poupon R, Soulé J, Benhamou Y, Grangé J, Coffin B. Efficacy of infliximab in Crohn's disease. Results of a retrospective multicenter study with a 15-month follow-up. Gastroentérologie Clinique et Biologique 2006;30:247-52. [DOI: 10.1016/s0399-8320(06)73161-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
70 Bewtra M, Su C, Lewis JD. Trends in hospitalization rates for inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol. 2007;5:597-601. [PMID: 17382602 DOI: 10.1016/j.cgh.2007.01.015] [Cited by in Crossref: 99] [Cited by in F6Publishing: 97] [Article Influence: 6.6] [Reference Citation Analysis]
71 Garcia-planella E, Domènech E, Esteve-comas M, Bernal I, Cabré E, Boix J, Gassull MA. Development of antinuclear antibodies and its clinical impact in patients with Crohn's disease treated with chimeric monoclonal anti-TNFα antibodies (infliximab): . European Journal of Gastroenterology & Hepatology 2003;15:351-4. [DOI: 10.1097/00042737-200304000-00003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
72 Papadakis KA, Treyzon L, Abreu MT, Fleshner PR, Targan SR, Vasiliauskas EA. Infliximab in the treatment of medically refractory indeterminate colitis: INFLIXIMAB FOR INDETERMINATE COLITIS. Alimentary Pharmacology & Therapeutics 2003;18:741-7. [DOI: 10.1046/j.1365-2036.2003.01739.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis]
73 Gisbert JP, Gomollón F. [Common errors in the management of the seriously ill patient with inflammatory bowel disease]. Gastroenterol Hepatol 2007;30:294-314. [PMID: 17493441 DOI: 10.1157/13101982] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
74 Kamm MA, Ng SC, De Cruz P, Allen P, Hanauer SB. Practical application of anti-TNF therapy for luminal Crohn’s disease. Inflamm Bowel Dis. 2011;17:2366-2391. [PMID: 21337669 DOI: 10.1002/ibd.21655] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
75 Mcnamara D, Brophy S, Hyland J. Perianal Crohn's disease and infliximab therapy. The Surgeon 2004;2:258-63. [DOI: 10.1016/s1479-666x(04)80094-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
76 Friesen CA, Calabro C, Christenson K, Carpenter E, Welchert E, Daniel JF, Haslag S, Roberts CC. Safety of Infliximab Treatment in Pediatric Patients with Inflammatory Bowel Disease: . Journal of Pediatric Gastroenterology and Nutrition 2004;39:265-9. [DOI: 10.1097/00005176-200409000-00008] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 2.7] [Reference Citation Analysis]
77 Bewtra M, Lewis JD. Safety Profile of IBD: Lymphoma Risks. Medical Clinics of North America 2010;94:93-113. [DOI: 10.1016/j.mcna.2009.08.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
78 Bank S, Julsgaard M, Abed OK, Burisch J, Broder Brodersen J, Pedersen NK, Gouliaev A, Ajan R, Nytoft Rasmussen D, Honore Grauslund C, Roug S, Galsgaard J, Sprogøe Høyer Finsen D, Lindby K, Sørensen J, Larsen L, Rohr Andersen M, Brandslund I, Thomassen M, Green A, Bo Bojesen A, Bek Sørensen S, Vogel U, Andersen V; Danish IBD Genetics Working Group. Polymorphisms in the NFkB, TNF-alpha, IL-1beta, and IL-18 pathways are associated with response to anti-TNF therapy in Danish patients with inflammatory bowel disease. Aliment Pharmacol Ther 2019;49:890-903. [PMID: 30811631 DOI: 10.1111/apt.15187] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
79 Panteleimonitis S, Ahmed J, Parker T, Qureshi T, Parvaiz A. Laparoscopic resection for primary and recurrent Crohn's disease: A case series of over 100 consecutive cases. International Journal of Surgery 2017;47:69-76. [DOI: 10.1016/j.ijsu.2017.09.055] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
80 Tiemi J, Komati S, Sdepanian VL. Effectiveness of infliximab in Brazilian children and adolescents with Crohn disease and ulcerative colitis according to clinical manifestations, activity indices of inflammatory bowel disease, and corticosteroid use. J Pediatr Gastroenterol Nutr 2010;50:628-33. [PMID: 20386321 DOI: 10.1097/MPG.0b013e3181bbf481] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
81 Arnott ID, McDonald D, Williams A, Ghosh S. Clinical use of Infliximab in Crohn's disease: the Edinburgh experience. Aliment Pharmacol Ther. 2001;15:1639-1646. [PMID: 11564005 DOI: 10.1046/j.1365-2036.2001.01092.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 2.7] [Reference Citation Analysis]
82 Pazianas M, Rhim AD, Weinberg AM, Su C, Lichtenstein GR. The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn‘s disease. Ann N Y Acad Sci. 2006;1068:543-556. [PMID: 16831950 DOI: 10.1196/annals.1346.055] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 3.1] [Reference Citation Analysis]
83 Vermeire S, Louis E, Carbonez A, Van Assche G, Noman M, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Rutgeerts P; Belgian Group of Infliximab Expanded Access Program in Crohn's Disease. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol 2002;97:2357-63. [PMID: 12358256 DOI: 10.1111/j.1572-0241.2002.05991.x] [Cited by in Crossref: 157] [Cited by in F6Publishing: 149] [Article Influence: 7.9] [Reference Citation Analysis]
84 Zwicker S, Martinez GL, Bosma M, Gerling M, Clark R, Majster M, Söderman J, Almer S, Boström EA. Interleukin 34: a new modulator of human and experimental inflammatory bowel disease. Clin Sci (Lond) 2015;129:281-90. [PMID: 25896238 DOI: 10.1042/CS20150176] [Cited by in Crossref: 53] [Cited by in F6Publishing: 26] [Article Influence: 7.6] [Reference Citation Analysis]
85 Michetti P, Stelle M, Juillerat P, Gassull M, Heil FJ, Stange E, Mottet C, Gonvers J, Pittet V, Vader J, Froehlich F, Felley C. Appropriateness of therapy for active Crohn's disease: Results of a multidisciplinary international expert panel—EPACT II. Journal of Crohn's and Colitis 2009;3:232-40. [DOI: 10.1016/j.crohns.2009.05.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
86 Xiao B, Ma P, Ma L, Chen Q, Si X, Walter L, Merlin D. Effects of tripolyphosphate on cellular uptake and RNA interference efficiency of chitosan-based nanoparticles in Raw 264.7 macrophages. J Colloid Interface Sci 2017;490:520-8. [PMID: 27918990 DOI: 10.1016/j.jcis.2016.11.088] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
87 Bewtra M, Lewis JD. Safety profile of IBD: lymphoma risks. Gastroenterol Clin North Am 2009;38:669-89. [PMID: 19913208 DOI: 10.1016/j.gtc.2009.07.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
88 Bank S, Andersen PS, Burisch J, Pedersen N, Roug S, Galsgaard J, Turino SY, Brodersen JB, Rashid S, Rasmussen BK. Associations between functional polymorphisms in the NFκB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease. Pharmacogenomics J. 2014;14:526-534. [PMID: 24776844 DOI: 10.1038/tpj.2014.19] [Cited by in Crossref: 76] [Cited by in F6Publishing: 74] [Article Influence: 9.5] [Reference Citation Analysis]
89 Ardizzone S, Bianchi Porro G. Biologic Therapy for Inflammatory Bowel Disease: . Drugs 2005;65:2253-86. [DOI: 10.2165/00003495-200565160-00002] [Cited by in Crossref: 178] [Cited by in F6Publishing: 178] [Article Influence: 10.5] [Reference Citation Analysis]
90 Ali T, Yun L, Rubin DT. Risk of post-operative complications associated with anti-TNF therapy in inflammatory bowel disease. World J Gastroenterol 2012; 18(3): 197-204 [PMID: 22294822 DOI: 10.3748/wjg.v18.i3.197] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
91 Zhou Y, He H, Wang P, Zhang T, Lin M, Wang H, Nie Y, Chen Y. Infliximab for the treatment of Crohn's disease: efficacy and safety in a Chinese single-center retrospective study. Eur J Gastroenterol Hepatol 2015;27:1270-5. [PMID: 26275085 DOI: 10.1097/MEG.0000000000000447] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
92 Makni A, Chebbi F, Ksantini R, Fétirich F, Bedioui H, Jouini M, Kacem M, Ben Mami N, Filali A, Ben Safta Z. Laparoscopic-assisted versus conventional ileocolectomy for primary Crohn's disease: Results of a comparative study. Journal of Visceral Surgery 2013;150:137-43. [DOI: 10.1016/j.jviscsurg.2012.10.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
93 Levine A, Milo T, Buller H, Markowitz J. Consensus and Controversy in the Management of Pediatric Crohn Disease: An International Survey: . Journal of Pediatric Gastroenterology and Nutrition 2003;36:464-9. [DOI: 10.1097/00005176-200304000-00008] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 2.7] [Reference Citation Analysis]
94 Bultman E, Kuipers EJ, Van Der Woude CJ. Systematic review: steroid withdrawal in anti-TNF-treated patients with inflammatory bowel disease: Systematic review: steroid withdrawal during anti-TNF treatment. Alimentary Pharmacology & Therapeutics 2010;32:313-23. [DOI: 10.1111/j.1365-2036.2010.04373.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
95 Limdi JK, Shaffer JL. How "NICE" were we with infliximab? Inflamm Bowel Dis 2005;11:705-6. [PMID: 15973126 DOI: 10.1097/01.mib.0000169733.88645.da] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
96 West RL, van der Woude CJ, Hansen BE, Felt-Bersma RJ, van Tilburg AJ, Drapers JA, Kuipers EJ. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2004;20:1329-1336. [PMID: 15606395 DOI: 10.1111/j.1365-2036.2004.02247.x] [Cited by in Crossref: 148] [Cited by in F6Publishing: 113] [Article Influence: 8.7] [Reference Citation Analysis]
97 Fow J, Grossman S. A comprehensive guide to patient-focused management strategies for Crohn disease. Gastroenterol Nurs 2007;30:93-8; quiz 98-100. [PMID: 17440309 DOI: 10.1097/01.SGA.0000267927.77545.bd] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
98 Veres G, Baldassano RN, Mamula P. Infliximab Therapy in Children and Adolescents with Inflammatory Bowel Disease: . Drugs 2007;67:1703-23. [DOI: 10.2165/00003495-200767120-00005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
99 Farrell RJ, Alsahli M, Jeen Y, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial. Gastroenterology 2003;124:917-24. [DOI: 10.1053/gast.2003.50145] [Cited by in Crossref: 401] [Cited by in F6Publishing: 345] [Article Influence: 21.1] [Reference Citation Analysis]
100 Zhu P, Sun JF, Gu YF, Chen HJ, Xu MM, Li YR, Yang BL. Combined therapy with early initiation of infliximab following drainage of perianal fistulising Crohn's disease: a retrospective cohort study. BMC Gastroenterol 2022;22:15. [PMID: 35012467 DOI: 10.1186/s12876-021-02078-9] [Reference Citation Analysis]
101 Alizadeh RF, Chaudhry HH, Li S, Jafari MD, Mills SD, Carmichael JC, Pigazzi A, Monson JR, Stamos MJ. Ileocolic Resection for Crohn's Disease: A Minimally Invasive Approach Claims Its Place. The American Surgeon 2018;84:1639-44. [DOI: 10.1177/000313481808401021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
102 Homan M, Baldassano RN, Mamula P. Managing complicated Crohn's disease in children and adolescents. Nat Rev Gastroenterol Hepatol 2005;2:572-9. [DOI: 10.1038/ncpgasthep0338] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 0.6] [Reference Citation Analysis]
103 Yu L, Yang X, Xia L, Zhong J, Ge W, Wu J, Liu H, Liu F, Liu Z. Infliximab preferentially induces clinical remission and mucosal healing in short course Crohn's disease with luminal lesions through balancing abnormal immune response in gut mucosa. Mediators Inflamm 2015;2015:793764. [PMID: 25873771 DOI: 10.1155/2015/793764] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
104 Hommes DW, van Deventer SJ. Targeting tumor necrosis factor-α in inflammatory bowel disease: why, how, and when? Current Opinion in Gastroenterology 2003;19:350-7. [DOI: 10.1097/00001574-200307000-00005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
105 Dubinsky MC, Reyes E, Ofman J, Chiou CF, Wade S, Sandborn WJ. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol. 2005;100:2239-2247. [PMID: 16181376 DOI: 10.1111/j.1572-0241.2005.41900.x] [Cited by in Crossref: 127] [Cited by in F6Publishing: 114] [Article Influence: 7.5] [Reference Citation Analysis]
106 Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm Bowel Dis. 2009;15:1264-1275. [PMID: 19235918 DOI: 10.1002/ibd.20899] [Cited by in Crossref: 96] [Cited by in F6Publishing: 89] [Article Influence: 7.4] [Reference Citation Analysis]
107 Vermeire S, Noman M, Van Assche G, Baert F, Van Steen K, Esters N, Joossens S, Bossuyt X, Rutgeerts P. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn’s disease: a prospective cohort study. Gastroenterology. 2003;125:32-39. [PMID: 12851868 DOI: 10.1016/s0016-5085(03)00701-7] [Cited by in Crossref: 238] [Cited by in F6Publishing: 63] [Article Influence: 12.5] [Reference Citation Analysis]
108 Ardizzone S, Maconi G, Colombo E, Manzionna G, Bollani S, Bianchi Porro G. Perianal fistulae following infliximab treatment: clinical and endosonographic outcome. Inflamm Bowel Dis. 2004;10:91-96. [PMID: 15168807 DOI: 10.1097/00054725-200403000-00005] [Cited by in Crossref: 76] [Cited by in F6Publishing: 69] [Article Influence: 4.2] [Reference Citation Analysis]
109 Belaiche J, Louis E. Severe lower gastrointestinal bleeding in Crohn's disease: successful control with infliximab. Am J Gastroenterol. 2002;97:3210-3211. [PMID: 12492221 DOI: 10.1111/j.1572-0241.2002.07143.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 0.9] [Reference Citation Analysis]
110 Han PD, Cohen RD. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. Drugs. 2004;64:1767-1777. [PMID: 15301561 DOI: 10.2165/00003495-200464160-00004] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 3.0] [Reference Citation Analysis]
111 Maggi E, Vultaggio A, Matucci A. Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol. 2011;7:55-63. [PMID: 21162650 DOI: 10.1586/eci.10.90] [Cited by in Crossref: 76] [Cited by in F6Publishing: 72] [Article Influence: 6.9] [Reference Citation Analysis]
112 Rubenstein JH, Chong RY, Cohen RD. Infliximab decreases resource use among patients with Crohn's disease. J Clin Gastroenterol. 2002;35:151-156. [PMID: 12172361 DOI: 10.1097/00004836-200208000-00007] [Cited by in Crossref: 86] [Cited by in F6Publishing: 75] [Article Influence: 4.3] [Reference Citation Analysis]
113 Murphy SJ, Wang L, Anderson LA, Steinlauf A, Present DH, Mechanick JI. Withdrawal of corticosteroids in inflammatory bowel disease patients after dependency periods ranging from 2 to 45 years: a proposed method. Alimentary Pharmacology & Therapeutics 2009;30:1078-86. [DOI: 10.1111/j.1365-2036.2009.04136.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
114 Cabré E. Indicaciones de la azatioprina (o 6-mercaptopurina) en la enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 2002;25:319-26. [DOI: 10.1016/s0210-5705(02)79028-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
115 Herrinton LJ, Liu L, Fireman B, Lewis JD, Allison JE, Flowers N, Hutfless S, Velayos FS, Abramson O, Altschuler A. Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998-2005. Gastroenterology. 2009;137:502-511. [PMID: 19445944 DOI: 10.1053/j.gastro.2009.04.063] [Cited by in Crossref: 73] [Cited by in F6Publishing: 76] [Article Influence: 5.6] [Reference Citation Analysis]
116 Dong L, Zuo L, Xia S, Gao S, Zhang C, Chen J, Zhang J. Reduction of liver tumor necrosis factor-alpha expression by targeting delivery of antisense oligonucleotides into Kupffer cells protects rats from fulminant hepatitis. J Gene Med 2009;11:229-39. [PMID: 19189285 DOI: 10.1002/jgm.1293] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
117 Sandborn WJ. Transcending conventional therapies: The role of biologic and other novel therapies. Inflamm Bowel Dis 2001;7:S9-S16. [DOI: 10.1002/ibd.3780070504] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
118 Stephens MC, Shepanski MA, Mamula P, Markowitz JE, Brown KA, Baldassano RN. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol. 2003;98:104-111. [PMID: 12526944 DOI: 10.1111/j.1572-0241.2003.07161.x] [Cited by in Crossref: 96] [Cited by in F6Publishing: 88] [Article Influence: 5.1] [Reference Citation Analysis]
119 Hyams JS, Markowitz J, Wyllie R. Reply. The Journal of Pediatrics 2002;140:637. [DOI: 10.1067/mpd.2002.123993] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
120 Xiao B, Laroui H, Ayyadurai S, Viennois E, Charania MA, Zhang Y, Merlin D. Mannosylated bioreducible nanoparticle-mediated macrophage-specific TNF-α RNA interference for IBD therapy. Biomaterials. 2013;34:7471-7482. [PMID: 23820013 DOI: 10.1016/j.biomaterials.2013.06.008] [Cited by in Crossref: 118] [Cited by in F6Publishing: 115] [Article Influence: 13.1] [Reference Citation Analysis]
121 Poggioli G, Laureti S, Pierangeli F, Rizzello F, Ugolini F, Gionchetti P, Campieri M. Local injection of Infliximab for the treatment of perianal Crohn’s disease. Dis Colon Rectum. 2005;48:768-774. [PMID: 15768185 DOI: 10.1007/s10350-004-0832-4] [Cited by in Crossref: 74] [Cited by in F6Publishing: 60] [Article Influence: 4.4] [Reference Citation Analysis]
122 Lionetti P, Bronzini F, Salvestrini C, Bascietto C, Canani RB, Dé Angelis GL, Guariso G, Martelossi S, Papadatou B, Barabino A. Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ther. 2003;18:425-431. [PMID: 12940928 DOI: 10.1046/j.1365-2036.2003.01672.x] [Cited by in Crossref: 117] [Cited by in F6Publishing: 103] [Article Influence: 6.2] [Reference Citation Analysis]
123 Present DH. Infliximab therapy for ulcerative colitis: many unanswered questions. Am J Gastroenterol 2001;96:2294-6. [PMID: 11513164 DOI: 10.1111/j.1572-0241.2001.04031.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
124 Burns JC, Mason WH, Hauger SB, Janai H, Bastian JF, Wohrley JD, Balfour I, Shen CA, Michel ED, Shulman ST. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr. 2005;146:662-667. [PMID: 15870671 DOI: 10.1016/j.jpeds.2004.12.022] [Cited by in Crossref: 199] [Cited by in F6Publishing: 137] [Article Influence: 11.7] [Reference Citation Analysis]
125 Lindberg A, Eberhardson M, Karlsson M, Karlén P. Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease. BMC Gastroenterol. 2010;10:73. [PMID: 20604939 DOI: 10.1186/1471-230x-10-73] [Cited by in Crossref: 30] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
126 Amodio G, Gregori S. Dendritic cells a double-edge sword in autoimmune responses. Front Immunol 2012;3:233. [PMID: 22876246 DOI: 10.3389/fimmu.2012.00233] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 4.1] [Reference Citation Analysis]
127 Fichera A, Michelassi F. Surgical treatment of Crohn's disease. J Gastrointest Surg. 2007;11:791-803. [PMID: 17562122 DOI: 10.1007/s11605-006-0068-9] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 2.8] [Reference Citation Analysis]
128 Parsi MA, Achkar JP, Richardson S, Katz J, Hammel JP, Lashner BA, Brzezinski A. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology. 2002;123:707-713. [PMID: 12198696 DOI: 10.1053/gast.2002.35390] [Cited by in Crossref: 189] [Cited by in F6Publishing: 162] [Article Influence: 9.5] [Reference Citation Analysis]
129 Devlin SM, Panaccione R. Adalimumab for the treatment of Crohn's disease. Expert Opin Biol Ther 2008;8:1011-9. [PMID: 18549330 DOI: 10.1517/14712598.8.7.1011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
130 Caspersen S, Elkjaer M, Riis L, Pedersen N, Mortensen C, Jess T, Sarto P, Hansen TS, Wewer V, Bendtsen F. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol. 2008;6:1212-1217; quiz 1176. [PMID: 18848503 DOI: 10.1016/j.cgh.2008.05.010] [Cited by in Crossref: 97] [Cited by in F6Publishing: 84] [Article Influence: 6.9] [Reference Citation Analysis]
131 Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology. 2004;126:402-413. [PMID: 14762776 DOI: 10.1053/j.gastro.2003.11.014] [Cited by in Crossref: 683] [Cited by in F6Publishing: 606] [Article Influence: 37.9] [Reference Citation Analysis]
132 Sandborn WJ, Hanauer S, Loftus EV, Tremaine WJ, Kane S, Cohen R, Hanson K, Johnson T, Schmitt D, Jeche R. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn’s disease. Am J Gastroenterol. 2004;99:1984-1989. [PMID: 15447761 DOI: 10.1111/j.1572-0241.2004.40462.x] [Cited by in Crossref: 181] [Cited by in F6Publishing: 173] [Article Influence: 10.1] [Reference Citation Analysis]
133 Wiese D, Lashner B, Seidner D. Measurement of nutrition status in Crohn's disease patients receiving infliximab therapy. Nutr Clin Pract 2008;23:551-6. [PMID: 18849561 DOI: 10.1177/0884533608323421] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
134 Wenzl HH, Reinisch W, Jahnel J, Stockenhuber F, Tilg H, Kirchgatterer A, Petritsch W. Austrian infliximab experience in Crohn's disease: a nationwide cooperative study with long-term follow-up. Eur J Gastroenterol Hepatol. 2004;16:767-773. [PMID: 15256978 DOI: 10.1097/01.meg.0000108355.41221.77] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
135 Lombardi DA, Feller ER, Shah SA. Medical management of inflammatory bowel disease in the new millennium. Compr Ther 2002;28:39-49. [DOI: 10.1007/s12019-002-0041-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
136 Matsumoto T, Iida M, Kohgo Y, Imamura A, Kusugami K, Nakano H, Fujiyama Y, Matsu T, Hibi T. Therapeutic efficacy of infliximab on active Crohn's disease under nutritional therapy. Scandinavian Journal of Gastroenterology 2009;40:1423-30. [DOI: 10.1080/00365520510023639] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
137 Carpenter E, Anne Jackson M, Friesen CA, Scarbrough M, Roberts CC. Crohn's-associated chronic recurrent multifocal osteomyelitis responsive to infliximab. The Journal of Pediatrics 2004;144:541-4. [DOI: 10.1016/j.jpeds.2003.12.038] [Cited by in Crossref: 72] [Cited by in F6Publishing: 49] [Article Influence: 4.0] [Reference Citation Analysis]
138 Mesko B, Poliska S, Váncsa A, Szekanecz Z, Palatka K, Hollo Z, Horvath A, Steiner L, Zahuczky G, Podani J, Nagy AL. Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease. Genome Med 2013;5:59. [PMID: 23809696 DOI: 10.1186/gm463] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
139 Bewtra M, Lewis JD. Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease. Expert Rev Clin Immunol 2010;6:621-31. [PMID: 20594135 DOI: 10.1586/eci.10.36] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
140 Seminerio JL, Loftus EV, Colombel JF, Thapa P, Sandborn WJ. Infliximab for Crohn’s disease: the first 500 patients followed up through 2009. Dig Dis Sci. 2013;58:797-806. [PMID: 23053885 DOI: 10.1007/s10620-012-2405-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
141 Kinney T, Rawlins M, Kozarek R, France R, Patterson D. Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions. Am J Gastroenterol 2003;98:608-12. [PMID: 12650795 DOI: 10.1111/j.1572-0241.2003.07286.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
142 Laine L, Hanauer SB. Considerations in the management of steroid-dependent Crohn’s disease. Gastroenterology 2003;125:906-10. [DOI: 10.1016/s0016-5085(03)01129-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
143 van Balkom BP, Schoon EJ, Stockbrügger RW, Wolters FL, van Hogezand RA, van Deventer SJ, Oldenburg B, van Dullemen HM, Russel MG. Effects of anti-tumour necrosis factor-alpha therapy on the quality of life in Crohn's disease. Aliment Pharmacol Ther. 2002;16:1101-1107. [PMID: 12030951 DOI: 10.1046/j.1365-2036.2002.01268.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
144 Braun J, Sieper J. Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases. Expert Opin Biol Ther 2003;3:141-68. [PMID: 12718738 DOI: 10.1517/14712598.3.1.141] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
145 Miele E, Markowitz JE, Mamula P, Baldassano RN. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr 2004;38:502-8. [PMID: 15097438 DOI: 10.1097/00005176-200405000-00008] [Cited by in Crossref: 93] [Cited by in F6Publishing: 84] [Article Influence: 5.2] [Reference Citation Analysis]
146 O'Meara S, Nanda KS, Moss AC. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20:1-6. [PMID: 24280879 DOI: 10.1097/01.mib.0000436951.80898.6d] [Cited by in Crossref: 98] [Cited by in F6Publishing: 35] [Article Influence: 12.3] [Reference Citation Analysis]
147 Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther. 2003;17:75-84. [PMID: 12492735 DOI: 10.1046/j.1365-2036.2003.01411.x] [Cited by in Crossref: 90] [Cited by in F6Publishing: 79] [Article Influence: 4.7] [Reference Citation Analysis]
148 Jensen-Jarolim E, Neumann C, Oberhuber G, Gscheidlinger R, Neuchrist C, Reinisch W, Zuberi RI, Penner E, Liu FT, Boltz-Nitulescu G. Anti-Galectin-3 IgG autoantibodies in patients with Crohn's disease characterized by means of phage display peptide libraries. J Clin Immunol 2001;21:348-56. [PMID: 11720007 DOI: 10.1023/a:1012240719801] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
149 Louis E, El Ghoul Z, Vermeire S, Dall’Ozzo S, Rutgeerts P, Paintaud G, Belaiche J, De Vos M, Van Gossum A, Colombel JF. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn’s disease. Aliment Pharmacol Ther. 2004;19:511-519. [PMID: 14987319 DOI: 10.1111/j.1365-2036.2004.01871.x] [Cited by in Crossref: 159] [Cited by in F6Publishing: 138] [Article Influence: 8.8] [Reference Citation Analysis]
150 Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB;  American Gastroenterological Association Clinical Practice Committee. AGA technical review on perianal Crohn's disease. Gastroenterology. 2003;125:1508-1530. [PMID: 14598268 DOI: 10.1016/j.gastro.2003.08.025] [Cited by in Crossref: 389] [Cited by in F6Publishing: 291] [Article Influence: 20.5] [Reference Citation Analysis]
151 Bewtra M, Lichtenstein GR. Infliximab use in Crohn’s disease. Expert Opinion on Biological Therapy 2005;5:589-99. [DOI: 10.1517/14712598.5.4.589] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
152 Lichtenstein GR. Approach to corticosteroid-dependent and corticosteroid-refractory Crohn‘s disease. Inflamm Bowel Dis. 2001;7 Suppl 1:S23-S29. [PMID: 11380040 DOI: 10.1002/ibd.3780070506] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 0.8] [Reference Citation Analysis]
153 Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Pritchard ML, Sandborn WJ. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621-630. [PMID: 16678077 DOI: 10.1016/j.cgh.2006.03.002] [Cited by in Crossref: 633] [Cited by in F6Publishing: 547] [Article Influence: 39.6] [Reference Citation Analysis]
154 Dziki A, Galbfach P. Crohn's disease--when to operate? Acta Chir Iugosl 2004;51:61-8. [PMID: 15771291 DOI: 10.2298/aci0402061d] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
155 Fichera A. Laparoscopic treatment of Crohn's disease. World J Surg. 2011;35:1500-1504. [PMID: 21384239 DOI: 10.1007/s00268-011-1031-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
156 Hommes DW, van de Heisteeg BH, van der Spek M, Bartelsman JFWM, van Deventer SJH. Infliximab Treatment for Crohn's Disease: One-Year Experience in a Dutch Academic Hospital: . Inflammatory Bowel Diseases 2002;8:81-6. [DOI: 10.1097/00054725-200203000-00002] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 2.7] [Reference Citation Analysis]
157 Fefferman DS, Lodhavia PJ, Alsahli M, Falchuk KR, Peppercorn MA, Shah SA, Farrell RJ. Smoking and immunomodulators do not influence the response or duration of response to infliximab in Crohn's disease. Inflamm Bowel Dis. 2004;10:346-351. [PMID: 15475741 DOI: 10.1097/00054725-200407000-00004] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 2.0] [Reference Citation Analysis]
158 Ardizzone S, Colombo E, Maconi G, Bollani S, Manzionna G, Petrone M, Bianchi Porro G. Infliximab in treatment of Crohn's disease: the Milan experience. Digestive and Liver Disease 2002;34:411-8. [DOI: 10.1016/s1590-8658(02)80038-x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]